This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cell Therapeutics CEO Should Resign: Opinion

Stocks in this article: CTIC

Even in an era of skyrocketing CEO compensation, your take-home pay is particularly galling because Cell Therapeutics' drug-development track record -- of which you're responsible -- is short on accomplishments but long on failures, setbacks and screw-ups.

Jim, if the fight against cancer is a war, you've been on the losing side of the battlefield your entire career.

Take pixantrone. This should have been a layup. Pixantrone belongs to a common and well-understood class of chemotherapy drugs. It's a me-too drug, for heck's sake! All Cell Therapeutics probably had to do to get pixantrone approved by the Food and Drug Administration was conduct a single, successful pivotal trial in a population of advanced lymphoma patients who were essentially out of treatment options. I'm hard pressed to think of a lower regulatory hurdle for a cancer drug.

But still, Cell Therapeutics, under your management, screwed up pixantrone's approval completely!

Yet in typical Bianco fashion, you grabbed the microphone Friday afternoon and acted as if nothing bad had happened. You didn't apologize for your colossal blunder. You took no responsibility for pixantrone's rejection. You simply moved on to the next fantastical story -- making yet more promises and proclamations about a new pixantrone pivotal trial that will be completed in a ridiculously short time period and with widespread support and participation from leading U.S. lymphoma specialists.

Jim, who are these U.S. doctors supporting pixantrone today? Please, don't tell us they're the same doctors who cared so little about pixantrone the first time around that they chose to enroll just eight patients across the entire country in the previous phase III study, according to the FDA.

And do you honestly expect us to believe that you're going to reach an agreement with FDA on a new pixantrone trial and line up research centers to run the trial and find the money to pay for the trial and enroll your first patient by September?

You called that timeline a "target" on Friday's conference call. I call it just another serving of Bianco B.S.

More malarkey from Friday's call, when you said, "We've been pleased with the expressed interest amongst large pharma companies, and the potential to co-develop and co-promote pixantrone with us in the U.S. and to take the lead on the product outside the U.S."

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,191.37 -195.84 -1.13%
S&P 500 2,002.16 -27.39 -1.35%
NASDAQ 4,637.9940 -43.5030 -0.93%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs